Showing 13 to 24 of 54 results
French Trial Shows Promise for Photobiostimulation in Parkinson's Treatment
A preliminary clinical trial in France is evaluating photobiostimulation to treat Parkinson's disease; initial results from seven patients show symptom stabilization in three with continuous light stimulation, offering a new non-invasive treatment approach.
French Trial Shows Promise for Photobiostimulation in Parkinson's Treatment
A preliminary clinical trial in France is evaluating photobiostimulation to treat Parkinson's disease; initial results from seven patients show symptom stabilization in three with continuous light stimulation, offering a new non-invasive treatment approach.
Progress
44% Bias Score
NeuroScientific Appoints CMO, Share Price Soars 371%
NeuroScientific Biopharmaceuticals appointed Dr. Catherine Cole as its chief medical officer, boosting its share price by 371 percent since June and accelerating development of its StemSmart stem cell technology for treating severe immune complications; interim results from a Crohn's disease trial a...
NeuroScientific Appoints CMO, Share Price Soars 371%
NeuroScientific Biopharmaceuticals appointed Dr. Catherine Cole as its chief medical officer, boosting its share price by 371 percent since June and accelerating development of its StemSmart stem cell technology for treating severe immune complications; interim results from a Crohn's disease trial a...
Progress
56% Bias Score
Exercise Significantly Reduces Colon Cancer Recurrence and Mortality
A new study shows that structured exercise programs for colon cancer patients after treatment resulted in a 28% lower risk of cancer recurrence and a 37% lower risk of death compared to the control group, suggesting a significant improvement in survival outcomes.
Exercise Significantly Reduces Colon Cancer Recurrence and Mortality
A new study shows that structured exercise programs for colon cancer patients after treatment resulted in a 28% lower risk of cancer recurrence and a 37% lower risk of death compared to the control group, suggesting a significant improvement in survival outcomes.
Progress
44% Bias Score
Groundbreaking Cancer Therapy Shows Remarkable Success in Late-Stage Prostate Cancer
A California study of 15 men with late-stage prostate cancer showed that 53% achieved complete remission using SYNC-T, a novel therapy involving tumor cryotherapy followed by localized immunotherapy; this exceeded expected survival rates, offering new hope for patients with limited treatment options...
Groundbreaking Cancer Therapy Shows Remarkable Success in Late-Stage Prostate Cancer
A California study of 15 men with late-stage prostate cancer showed that 53% achieved complete remission using SYNC-T, a novel therapy involving tumor cryotherapy followed by localized immunotherapy; this exceeded expected survival rates, offering new hope for patients with limited treatment options...
Progress
48% Bias Score
Car T-cell Immunotherapy Extends Life of Gastric Cancer Patients by 40%
A world-first clinical trial in China shows that Car T-cell immunotherapy significantly increases the lifespan of patients with advanced gastric or gastro-oesophageal junction cancer by approximately 40%, offering a potential paradigm shift in the treatment of solid tumors, according to results publ...
Car T-cell Immunotherapy Extends Life of Gastric Cancer Patients by 40%
A world-first clinical trial in China shows that Car T-cell immunotherapy significantly increases the lifespan of patients with advanced gastric or gastro-oesophageal junction cancer by approximately 40%, offering a potential paradigm shift in the treatment of solid tumors, according to results publ...
Progress
48% Bias Score
Immunotherapy Drug Shows Significant Improvement in Head and Neck Cancer Survival
A clinical trial shows that the immunotherapy drug pembrolizumab significantly improves survival rates and reduces the spread of advanced head and neck cancer by training the immune system to fight the cancer cells, offering a major breakthrough after two decades with little progress in treatment me...
Immunotherapy Drug Shows Significant Improvement in Head and Neck Cancer Survival
A clinical trial shows that the immunotherapy drug pembrolizumab significantly improves survival rates and reduces the spread of advanced head and neck cancer by training the immune system to fight the cancer cells, offering a major breakthrough after two decades with little progress in treatment me...
Progress
44% Bias Score
Stem-Cell Treatment Shows Promise for Reversing Hearing Loss
A UK clinical trial is testing a new stem-cell treatment for hearing loss caused by auditory nerve damage, injecting lab-grown stem cells into the inner ear to regenerate damaged nerve cells; the trial, involving 20 profoundly deaf patients, will test the treatment's efficacy in reversing hearing lo...
Stem-Cell Treatment Shows Promise for Reversing Hearing Loss
A UK clinical trial is testing a new stem-cell treatment for hearing loss caused by auditory nerve damage, injecting lab-grown stem cells into the inner ear to regenerate damaged nerve cells; the trial, involving 20 profoundly deaf patients, will test the treatment's efficacy in reversing hearing lo...
Progress
44% Bias Score
Glioblastoma Patient Shows No Signs of Cancer After Immunotherapy Treatment
A 43-year-old man, Ben Trotman, diagnosed with glioblastoma in October 2022, is cancer-free following an experimental immunotherapy treatment at University College London Hospital, defying the typical 12-18 month survival rate for this aggressive brain cancer.
Glioblastoma Patient Shows No Signs of Cancer After Immunotherapy Treatment
A 43-year-old man, Ben Trotman, diagnosed with glioblastoma in October 2022, is cancer-free following an experimental immunotherapy treatment at University College London Hospital, defying the typical 12-18 month survival rate for this aggressive brain cancer.
Progress
48% Bias Score
Wegovy's 7.2mg Dose Shows 20.7% Weight Loss in Obese Individuals: Novo Nordisk
Novo Nordisk's STEP UP trial, presented at the ADA 2024 Scientific Sessions, demonstrated that a 7.2mg dose of semaglutide (Wegovy) led to a 20.7% average weight loss in obese individuals without diabetes after 72 weeks, with a third achieving at least 25% weight reduction compared to placebo; the c...
Wegovy's 7.2mg Dose Shows 20.7% Weight Loss in Obese Individuals: Novo Nordisk
Novo Nordisk's STEP UP trial, presented at the ADA 2024 Scientific Sessions, demonstrated that a 7.2mg dose of semaglutide (Wegovy) led to a 20.7% average weight loss in obese individuals without diabetes after 72 weeks, with a third achieving at least 25% weight reduction compared to placebo; the c...
Progress
52% Bias Score
New 'Smart Bomb' Cancer Treatment Shows Significant Improvement in HER2-Positive Metastatic Breast Cancer
A clinical trial involving nearly 400 patients with HER2-positive metastatic breast cancer showed that a new treatment combining T-DXd and pertuzumab reduced disease progression or death risk by 44%, with 15% achieving complete remission, compared to 8.5% with standard therapy; the findings will be ...
New 'Smart Bomb' Cancer Treatment Shows Significant Improvement in HER2-Positive Metastatic Breast Cancer
A clinical trial involving nearly 400 patients with HER2-positive metastatic breast cancer showed that a new treatment combining T-DXd and pertuzumab reduced disease progression or death risk by 44%, with 15% achieving complete remission, compared to 8.5% with standard therapy; the findings will be ...
Progress
48% Bias Score
Exercise Significantly Reduces Colon Cancer Recurrence Risk
A study of nearly 900 colon cancer patients found that a structured exercise program following surgery and chemotherapy reduced the risk of recurrence, new diagnosis, or death by 28%, suggesting exercise as a vital post-treatment therapy.
Exercise Significantly Reduces Colon Cancer Recurrence Risk
A study of nearly 900 colon cancer patients found that a structured exercise program following surgery and chemotherapy reduced the risk of recurrence, new diagnosis, or death by 28%, suggesting exercise as a vital post-treatment therapy.
Progress
28% Bias Score
Immunotherapy Drug Doubles Cancer-Free Survival Time for Advanced Head and Neck Cancer
A clinical trial shows that the immunotherapy drug pembrolizumab doubles the time patients with advanced head and neck cancer live without their cancer returning, offering a significant breakthrough after two decades of stagnant treatment options.
Immunotherapy Drug Doubles Cancer-Free Survival Time for Advanced Head and Neck Cancer
A clinical trial shows that the immunotherapy drug pembrolizumab doubles the time patients with advanced head and neck cancer live without their cancer returning, offering a significant breakthrough after two decades of stagnant treatment options.
Progress
44% Bias Score
Showing 13 to 24 of 54 results